Oncolytics Biotech is a biotechnology company that focuses on developing treatments for cancer using oncolytic viruses. Oncolytic viruses are genetically modified or naturally occurring viruses that selectively infect and kill cancer cells while sparing normal healthy cells. The company’s primary aim is to advance innovative therapies that leverage these viruses to enhance the immune response against tumors, potentially improving the effectiveness of cancer treatments. Oncolytics Biotech conducts research and clinical trials to evaluate the safety and efficacy of its oncolytic virus-based therapies, contributing to the broader field of cancer immunotherapy.
**Oncolytics Biotech Inc. (TSE:ONC)** has been making headlines after its shares surged past the significant threshold of its two hundred-day moving average. During Friday's trading session, the stock peaked at…